Belinostat abstracts for American Association for Cancer Research 2015
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that preclinical and clinical data on belinostat will be presented at the 2015 American Association for Cancer Research (AACR) Annual Meeting (April 18-22, 2015) in Philadelphia (Pennsylvania), USA.
Preclinical and clinical abstracts involving belinostat will be featured at the AACR 2015. To be highlighted are especially abstracts no. 114 and 5480. Abstract no. 114 concerns the mass balance study of 14C-belinostat in patients with recurrent or progressive malignancy. The aim of the study is to evaluate the excretion (mass balance) and pharmacokinetics of belinostat and to further understand the drug’s metabolism. The study is a post-marketing requirement study set by the US Food and Drug Administration (FDA). The study’s top-line results show that the study was positively conducted. Abstract 5480 concerns the clinical toxicity of belinostat, which shows that belinostat has a good safety profile.
The studies supporting these abstracts were conducted on belinostat in different cancer indications and have generated relevant and robust preclinical and clinical data on the product’s profile, alone or in combination with other chemotherapies. These first data will much help supporting and finalizing the best development plan for belinostat and already advocate for the selection of new promising orphan oncology indications.
The involvement of the large number of investigators in these studies demonstrates the scientific and clinical interest on the product and is encouraging for the future potential of clinical sites to enroll.
“Already registered and marketed in the US for the treatment of peripheral T-cell lymphoma, belinostat has furthermore a strong potential research focus and several potential cancer indications. The product’s development plan is being built based on these assets and perfectly fits with our strategy to build a robust and diversified pipeline focused on the orphan oncology”, comments Judith Greciet, CEO of Onxeo.
2015 AACR Abstract Belinostat 114